Startup profile · funding coverage
NorthStar Medical Technologies funding, valuation and investors
Radiopharmaceutical infrastructure company producing medical radioisotopes and providing clinical and commercial drug-manufacturing services.
Keep track of NorthStar Medical Technologies
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Not publicly disclosed
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · Beloit, Wisconsin, United States
Overview
NorthStar Medical Technologies develops and manufactures medical radioisotopes used in diagnostic imaging and targeted cancer therapies. Its Beloit, Wisconsin campus combines commercial-scale isotope production with radiopharmaceutical CDMO capabilities, including work with actinium-225 and copper-67.
Why NorthStar Medical Technologies is interesting
NorthStar is building supply-chain infrastructure for radiopharmaceutical oncology, where limited availability of isotopes such as actinium-225 can constrain clinical trials and commercial deployment.
Product & use cases
NorthStar produces radioisotopes and provides development, clinical-manufacturing and commercial-manufacturing services for radiopharmaceutical programs. The company reports routine commercial-scale production of no-carrier-added actinium-225 using electron-accelerator technology.
- Supply of actinium-225 and copper-67 for radiopharmaceutical drug development and clinical trials.
- Clinical and commercial radiopharmaceutical contract development and manufacturing.
- Medical-isotope production supporting targeted alpha therapies and diagnostic imaging.
Key facts
- Announced a multi-year growth-capital facility of up to $185 million from Hercules Capital on September 29, 2026, including $100 million funded upfront.
- Company says it routinely produces no-carrier-added actinium-225 at commercial scale using electron accelerators.
- Operates co-located isotope-production and radiopharmaceutical CDMO infrastructure in Beloit, Wisconsin.
Funding history (newest first)
Growth capital facility / venture debt
2026-09-29 Up to $185 million; $100 million funded upfrontSource: https://www.northstarnm.com/northstar-secures-growth-financing/
Investors in our directory
Funds linked from NorthStar Medical Technologies's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Co-location of commercial-scale isotope production and radiopharmaceutical CDMO services may reduce handoffs between isotope suppliers and drug manufacturers. Its electron-accelerator production route is differentiated from reactor, cyclotron and legacy-stockpile supply.
NorthStar competes with isotope producers and radiopharmaceutical supply platforms including TerraPower Isotopes, Niowave, Ionetix and Eckert & Ziegler. Competitive differentiation depends on radionuclidic purity, reliable scale, regulatory execution and the ability to supply clinical through commercial volumes.
-
TerraPower Isotopes direct
Develops and supplies actinium-225 and other medical isotopes.
-
Niowave direct
US producer of medical radioisotopes including actinium-225.
-
Ionetix direct
Cyclotron-based isotope producer expanding actinium-225 capacity.
-
Eckert & Ziegler direct
Established international medical-isotope and radiopharmaceutical supplier.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover NorthStar Medical Technologies's financing or category context.
FAQs about NorthStar Medical Technologies
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.